Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Authors
Keywords
Head and neck cancer, Metastatic, Immunotherapy, SBRT, Durvalumab, Tremelimumab
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-14
DOI
10.1186/s12885-019-5266-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013
- (2017) Nerina Denaro et al. ONCOLOGY
- Stereotactic Body Radiation Therapy for Treatment of Spinal Bone Metastasis
- (2016) Yasemin Benderli Cihan Asian Pacific Journal of Cancer Prevention
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies
- (2016) Jing Zhao et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- (2016) Daniel R Gomez et al. LANCET ONCOLOGY
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- (2015) A. Filatenkov et al. CLINICAL CANCER RESEARCH
- Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis
- (2015) E.R. Young et al. CLINICAL OTOLARYNGOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- The biology and treatment of oligometastatic cancer
- (2015) Diane K. Reyes et al. Oncotarget
- Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
- (2015) Jill Gilbert et al. Journal for ImmunoTherapy of Cancer
- Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
- (2015) Robert L Ferris et al. Journal for ImmunoTherapy of Cancer
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- The Effect of Radiation on the Immune Response to Cancers
- (2014) Bonggoo Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
- (2014) Encouse B Golden et al. OncoImmunology
- Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
- (2013) Chao-Yi Wu et al. CLINICAL CANCER RESEARCH
- Multicentre results of stereotactic body radiotherapy for secondary liver tumours
- (2013) Betul Berber et al. HPB
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
- (2013) E. B. Golden et al. Cancer Immunology Research
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- The Canadian Association of Radiation Oncology Scope of Practice Guidelines for Lung, Liver and Spine Stereotactic Body Radiotherapy
- (2012) A. Sahgal et al. CLINICAL ONCOLOGY
- Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer
- (2012) Aleksandar F. Dragovic et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial
- (2012) Xin Shelley Wang et al. LANCET ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligometastases revisited
- (2011) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?
- (2010) Hiroshi Onishi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Stereotactic body radiation therapy: a novel treatment modality
- (2009) Simon S. Lo et al. Nature Reviews Clinical Oncology
- Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer
- (2008) Frank J. Lagerwaard et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started